Implementation, communication, ethics, and family-history practice. For counsellors and genetic nurses keeping up with the wider conversation.
101 stories · Last updated
Regeneron's antibody treatment for fibrodysplasia ossificans progressiva — an ultra-rare genetic disorder in which bone forms progressively in soft tissue — has received FDA approval under the brand name Pasatru.
A preprint reports two novel deep-intronic variants in PCDH15 that disrupt splicing in Usher syndrome patients who had previously received no genetic diagnosis, and demonstrates antisense oligonucleotide rescue in a minigene model.
NHS England begins distributing home HPV self-sampling kits to women aged 30–65 who have not responded to cervical screening invitations, aiming to increase uptake.
The US Food and Drug Administration has again paused a Regenxbio clinical trial for Hunter syndrome following new safety signals, underscoring ongoing challenges in adeno-associated virus gene therapy development.
Specialists in gene editing have questioned the study design and technical choices made by Huidagene Therapeutics in a Duchenne muscular dystrophy trial in which a patient died.
A preprint demonstrates that the minor spliceosome snRNA U4atac controls cilium biogenesis in the developing zebrafish brain by regulating splicing of minor introns in two ciliary genes, connecting RNU4ATAC-associated syndromes to ciliopathy.
A random forest classifier integrating protein structural context, evolutionary conservation, and gene constraint offers calibrated PP3/BP4 thresholds for variant classification.
A PHG Foundation analysis sets out why the pathway for UK participation in the EU's cross-border health data framework is still legally and politically unclear.
A preprint describes an extended VAMP-seq approach that systematically measures the protein stability consequences of amino acid substitutions in zeta-globin, with a computational framework to predict effects across related paralogues.
A bioRxiv preprint describes a collection of characterised human cell lines bearing NF1 variants — including variants of uncertain significance — made freely available to the research community.
Research shows that haploinsufficiency of the transcription factor TBX5 unravels the three-dimensional chromatin architecture required for normal cardiac development, offering a mechanism for variable expressivity in congenital heart disease.
A bioRxiv preprint examines how heterozygosity or homozygosity for the MYBPC3 p.A31P variant shapes the severity and phenotype of hypertrophic cardiomyopathy in Maine Coon cats, reinforcing their value as a large-animal model for the human condition.
An FDA advisory committee is scheduled to weigh the evidence for Grail's Galleri blood-based multi-cancer detection test, a decision with broad implications for the emerging field of cell-free DNA screening.
A bioRxiv preprint argues that existing variant classification frameworks assign a single verdict regardless of inheritance state, and uses lipoprotein lipase variants as a proof-of-concept for context-aware interpretation.
A new PHG Foundation commentary examines how recent sequencing technology advances are reshaping expectations of what constitutes adequate genomic testing.
Skylark Bio has initiated a gene therapy trial targeting GJB2 mutations — one of the most common genetic causes of congenital deafness — as multiple companies pursue different mutation-specific approaches.
Aurora Therapeutics, which aimed to industrialise bespoke CRISPR gene-editing treatments modelled on the Baby KJ case, has abandoned its programme, citing regulatory demands that a small company could not meet.
A delayed report of a second fatality in an investigator-led gene-editing study in China has intensified international debate about oversight standards and trial transparency.
A bioRxiv preprint describes a frameshift knock-in mouse model of MFM13, a rare autosomal dominant myopathy, and tests trehalose as a candidate therapy targeting the chaperone-assisted autophagy pathway.
Replimune's oncolytic virus therapy RP1 has received FDA approval for advanced melanoma after two prior rejections, completing a prolonged regulatory journey reported by Stat News.
A new policy analysis from the PHG Foundation considers what an updated, polygenic-score-integrated BOADICEA model means for how familial breast-cancer risk should be assessed at a population level.
A study reports that blood cancers destined to worsen carry identifiable genomic changes long before clinical progression, potentially helping researchers distinguish pathological from age-related haematopoietic changes.
A major genome-wide study has expanded the known genetic architecture of hyperemesis gravidarum to ten risk genes, several of which implicate appetite and nausea regulation pathways.
A bioRxiv preprint identifies a transient window of extreme TCOF1 dosage-sensitivity in cranial neural crest cells, offering a mechanistic explanation for the tissue-specific effects of Treacher Collins syndrome.
A controlled mouse study published this week provides direct experimental evidence that germline genetic background influences both whether and how cancer develops after the same DNA-damaging event.
A new briefing from the PHG Foundation at the University of Cambridge outlines recommendations for EU and national governments seeking to embed genomics-informed prevention into health systems.
Multiple companies are pursuing CRISPR and gene-editing approaches for AATD, a rare inherited lung and liver disease, amid patent disputes, a start-up exodus, and US–China competitive tensions reported by Stat News.
The three institutions have announced a joint initiative to develop gene therapies targeting rare diseases, pooling expertise across genomics, clinical research, and model-organism biology.
A study finds that the longevity-associated APOE2 allele reduces DNA damage accumulation in brain cells and aids neuronal stress recovery, pointing towards a potential mechanistic target for Alzheimer's research.
A preprint describes an anticodon-edited tRNA that achieves up to 86% readthrough across 13 clinically relevant Arg-to-stop variants, offering a gene-agnostic strategy for a prevalent subclass of inherited retinal disease.
A bioRxiv preprint reports that damaging variants in the glutamate-rich domain of the cardiac splice regulator RBM20 are not corrected by gene replacement, suggesting they act via a different mechanism from the better-studied RS-domain variants.
A patient advocate writing in Stat News argues that regulatory tools designed to accelerate rare-disease approvals are instead creating new barriers for limb girdle muscular dystrophy treatments.
A bioRxiv preprint integrating whole-genome sequencing, transcriptomic, and epigenomic data proposes that an overlooked non-coding regulatory signal may help explain why GBA1 coding variants substantially raise Parkinson's disease risk.
Around 200 patients a year, including infants, will gain access to two newly approved treatments for histiocytic neoplasms after NHS England commissioning decisions.
A bioRxiv preprint identifies aberrant expression of the long non-coding RNA Hsrω-n as a contributor to neuronal toxicity in a Drosophila model of fragile X-associated tremor/ataxia syndrome.
A new theoretical framework published in PLOS Genetics uses age-specific penetrance data to improve on the standard 50% carrier-risk figure given to relatives of C9orf72 mutation carriers.
Seven research laboratories will share ARPA-H funding aimed at accelerating individually tailored gene-editing therapies for patients with rare genetic conditions.
A Stat News newsletter item notes a reported death in a gene-editing trial in China, adding further pressure on international oversight bodies days after a second child death was already covered by Genetic Current.
A bioRxiv preprint describes a zinc finger nuclease approach that inserts a functional rhodopsin gene copy regardless of which of nearly 100 pathogenic RHO variants a patient carries, aiming to circumvent the mutational heterogeneity that limits variant-specific therapies.
Screening of 1,562 Finnish extended families links heterozygous INTS6 variants to mild intellectual disability, implicating the Integrator complex phosphatase module in a neurodevelopmental disorder.
Roche has ended its gene-silencing efforts targeting Huntington's disease, a setback for a field that has seen several high-profile programme failures in recent years.
Preclinical research finds that combining telmisartan with olaparib boosts anticancer and immune effects, potentially broadening the PARP inhibitor's utility beyond BRCA1/2-related cancers, with human trials already under way.
A preprint from Cold Spring Harbor Laboratory describes a zebrafish system that uses functional surrogacy to model vascular Ehlers-Danlos syndrome and reclassify COL3A1 variants where pathogenicity is unclear.
A preprint reports that dizygotic twins in a consanguineous family carry both a novel EPS8 variant linked to hearing loss and an HPDL variant associated with neurodevelopmental disorder, illustrating how multilocus pathogenic variation can produce complex overlapping phenotypes.
Columbia University researchers report that a specific genetic variant may accelerate heart valve damage in people with degenerative mitral regurgitation who also take SSRI antidepressants.
A trainee-led bioRxiv preprint reports that exposure to the 2023 NASEM guidelines on population descriptors improves ethical awareness but does not eliminate fundamental misunderstandings about the relationship between race and ancestry.
The departure of Vijay Kumar from the FDA's Office of Therapeutic Products follows a broader leadership shakeup at the agency and raises questions about continuity in gene therapy oversight.
A new study reported by Cancer Research UK finds evidence that people under 55 are biologically ageing more rapidly than older cohorts, a trend researchers say may be connected to increasing rates of early-onset cancer.
Researchers have assessed the functional effects of missense variants of uncertain significance in the ECD1 region of ABCA4, which is implicated in Stargardt disease and other inherited retinal conditions.
Orca Bio has received FDA approval for a T-cell therapy designed to lower the risk of graft-versus-host disease in blood cancer patients undergoing haematopoietic stem cell transplantation.
Researchers have used base-editing and prime-editing tools in early human embryos to probe developmental gene function, achieving improved on-target precision while prompting renewed ethical scrutiny.
David Meek's acquisition of collapsed gene-therapy company Bluebird Bio has been rebranded as Genetix, with the new entity reporting early profitability in sickle cell and other programmes.
An opinion piece in STAT News marks the death of Joseph Fraumeni Jr., the NCI epidemiologist whose work with Frederick Li identified the hereditary cancer syndrome that bears their names.
The US Food and Drug Administration has reversed its earlier opposition, allowing UniQure to file its investigational RNA-interference treatment for Huntington's disease for regulatory review.
A preprint using structural modelling across more than one million genomes classifies over 600 ARID1B missense variants as damaging to protein interactions or stability, offering a resource for interpreting the large majority of variants that currently lack clinical classification.
The US Food and Drug Administration has reversed its earlier rejection and will re-examine Regenxbio's experimental gene therapy for Hunter syndrome, a rare and life-limiting childhood disorder.
Cancer Research UK reports that new data provide the strongest evidence to date that the UK HPV vaccination programme is reducing not only cervical cancer incidence but cervical cancer mortality.
The new gene-editing startup is targeting alpha-1 antitrypsin deficiency, a rare inherited lung and liver disease, following a reverse-merger and a licensing deal with a Chinese biotech company.
Analysis of admixed Brazilian elderly cohorts finds deviations from expected APOE ε2 genotype frequencies, raising questions about whether its longevity-protective role generalises beyond European-ancestry populations.
A preprint from Cold Spring Harbor Laboratory applies saturation genome editing to reclassify more than 9,000 variants of uncertain significance in two hereditary cancer genes.
Michelle Sie Whitten of the Global Down Syndrome Foundation writes in STAT News that women receiving a prenatal Down syndrome diagnosis are routinely given outdated or incomplete information about life expectancy and quality of life.
A PLOS Genetics study from researchers at Children's National Hospital and the Stowers Institute provides the largest functional dataset to date for variants in ASS1, the gene disrupted in citrullinaemia type I, and reveals unexpected epistatic interactions between variants.
Back-to-back bioRxiv preprints use large clinical datasets and nasal airway cell measurements to examine how CFTR channel function relates to disease severity and to respiratory symptoms in carriers.
Researchers report that somatic mutations associated with haematological malignancies could trigger neuroinflammation implicated in Alzheimer's disease, suggesting a previously unrecognised mechanistic overlap between the two conditions.
A STAT News opinion piece argues that recent technical progress in human embryo editing demands structured ethical debate before the science moves further ahead.
The world's first randomised trial of a multi-cancer early detection blood test did not meet its primary endpoint, though commentators argue the results carry important signals for the field of early-detection genomics.
A preprint reports that in vivo CRISPR editing targeting the mismatch repair gene Msh3 slowed somatic CAG repeat expansion and mitigated disease pathology in a Huntington's disease mouse model.
The UK National Screening Committee has endorsed a risk-stratified approach to prostate cancer screening, focusing on men who carry a BRCA2 pathogenic variant and have a relevant family history of cancer.
Researchers have identified a compound that blocks the DNA repair mechanism cancer cells exploit to survive treatment, potentially reversing resistance to PARP inhibitor therapies.
A preprint leveraging the gnomAD v4 dataset of over 730,000 exomes proposes improved methods for characterising elevated mutation rates and predicting the pathogenicity of rare coding variants.
The antibody-drug conjugate mirvetuximab soravtansine has been added to the NHS England treatment portfolio for platinum-resistant ovarian cancer — the first new approved option in this setting in more than two decades.
Researchers developed a probabilistic framework to assess how accurately polygenic predictions of observable traits could be used to re-identify an anonymised genome, finding the practical risk lower than some prior estimates suggested.
A preprint reports that 4% of Rwandan breast cancer cases in a 175-woman cohort carry a single recurrent BRCA1 frameshift variant tracing to a common ancestral haplotype of around 581 kb.
A preprint reports that base editors — which introduce single-letter DNA changes without cutting both DNA strands — avoided the aneuploidy and large deletions seen with standard CRISPR-Cas9 in early human embryos.
Analysis of polr3a mutant zebrafish shows that loss of this Pol III subunit specifically impairs neural crest cell-derived craniofacial structures, clarifying how POLR3-related disease variants cause tissue-specific developmental defects.
A STAT News commentary argues that the bottleneck for transformative gene therapies is no longer biological but financial, calling for structural reform in how payers and health systems fund one-time curative treatments.
A bioRxiv preprint from 2026 proposes that astrocytes — not only neurons — may contribute to the pathophysiology of CDKL5 Deficiency Disorder, a rare developmental epileptic encephalopathy.
Researchers have posted a preprint describing MAGI, a computational method that uses genomic foundation models to generate mechanistic annotations of genetic variants — aiming to move beyond binary pathogenicity labels towards interpretable biological explanations.
Researchers studying the Mediator Kinase Module find that heterozygous MED13L variants consistently produce aberrant cyclin C localisation and mitochondrial dysfunction across multiple patient-derived cell models.
A University of California San Francisco team has applied to the FDA for permission to run a small first-in-human trial of gene therapy delivered before birth for a rare lysosomal storage disorder.
New NHS England data show that mobile scanning units deployed at supermarkets, sports stadiums and high streets have detected 10,678 lung cancers, more than three-quarters at stages one or two.
The D4Z4caster assay uses targeted bisulfite sequencing of the D4Z4 repeat array to stratify individuals who may carry the epigenetic hallmarks of facioscapulohumeral muscular dystrophy.
A Cancer Research UK commentary argues that structural and funding barriers are slowing the translation of population-level genetic and lifestyle risk data into cancer prevention strategies.
A new Cancer Research UK analysis argues that targeting the earliest detectable cancer-driving changes in high-risk individuals could prevent more cancers, but requires coordinated policy support to reach its potential.
Cancer Research UK analysis shows melanoma incidence has reached its highest recorded level in the UK, raising questions about prevention, surveillance, and the role of genetic risk factors.
A bioRxiv preprint reports exploratory and confirmatory factor analysis of the EAGL measure in 2,708 US participants, introducing a knowledge comprehension subscale alongside standard subjective and objective knowledge components.
Nusinersen and risdiplam will be routinely available on the NHS in England following an evidence-collection access scheme, giving families with spinal muscular atrophy long-term certainty.
A commentary in Nature Human Behaviour challenges widespread framing of polygenic risk scores as fixed biological traits, with implications for research communication and public understanding.
A PHG Foundation analysis highlights how genetic variants affecting red blood cell biology can cause HbA1c to misclassify diabetes risk, with disproportionate impact across ancestry groups.
Additional reporting and commentary from ASCO 2026 consolidates the picture around Revolution Medicines' daraxonrasib, with coverage noting that demand from patients is already outpacing access to the investigational drug.
A new systematic review published in 2026 concludes that prostate-specific antigen blood testing likely reduces the risk of death from prostate cancer, though over-diagnosis and over-treatment remain concerns.
A bioRxiv preprint describes a homozygous missense variant in MGME1 — a nuclear-encoded gene essential for mitochondrial DNA maintenance — identified in five affected individuals from unrelated South Indian families presenting with multi-systemic mitochondrial disease.
A bioRxiv preprint reports that inhibiting the epigenetic regulator SMCHD1 can reactivate silenced maternal copies of genes in the Prader-Willi syndrome imprinted locus in cellular and animal models.
A bioRxiv preprint describes sustained preservation of retinal integrity and function following AAV8-delivered PEX1 gene therapy in a murine model of Zellweger spectrum disorder.
A five-laboratory evaluation published as a preprint on bioRxiv finds that an amplification-based Oxford Nanopore workflow can reliably detect clinically relevant variants in genes with architectures that challenge short-read methods.
A paper in Nature Medicine reports that Australia has passed legislation preventing life insurers from using genetic test results to discriminate against applicants — a significant regulatory development with implications for genetic testing uptake.
Case reports published in Communications Medicine describe clinical use of the MEK inhibitor trametinib in two patients with multiple non-ossifying fibromas attributed to somatic mosaic KRAS mutations.
Researchers report that the histone acetyltransferase KAT6A is required for normal expression of developmental control genes in neural stem and progenitor cells, with implications for understanding Arboleda-Tham syndrome.
A paper published in the European Journal of Human Genetics examines variation in the training, registration, and scope of practice of genetic counsellors across European countries and proposes steps towards harmonisation.
An author correction has been issued for the Nature Genetics paper identifying biallelic RNU4-2 variants as a cause of a recessive neurodevelopmental syndrome with distinct white matter changes.
Researchers report findings from opportunistic screening of healthy controls in an Australian biobank, examining the yield and implications of returning genomic results outside a clinical referral pathway.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List